Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas

Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma

(2021) Livnat Jerby-Arnon et al.   NATURE MEDICINE

Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study

(2021) Yaolin Chen et al.   BMC CANCER

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in tridimensional and zebrafish models

(2021) Alessandro De Vita et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study

(2021) Maria A. Smolle et al.   BRITISH JOURNAL OF CANCER

Advances in the management of alveolar soft part sarcoma

(2021) Geraldine O’Sullivan Coyne et al.   CURRENT PROBLEMS IN CANCER

Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention

(2021) Marcella Tazzari et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.

(2021) Antoine Italiano et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

(2021) Abdul Rafeh Naqash et al.   JOURNAL OF CLINICAL ONCOLOGY

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

(2021) Jean-Yves Blay et al.   JOURNAL OF CLINICAL ONCOLOGY

CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment

(2021) Tomohiro Fujiwara et al.   MOLECULAR CANCER THERAPEUTICS

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

(2021) Michael J Wagner et al.   Journal for ImmunoTherapy of Cancer

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy

(2021) Cristina Belgiovine et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

(2020) Emily Z. Keung et al.   CLINICAL CANCER RESEARCH

B cells are associated with survival and immunotherapy response in sarcoma

(2020) Florent Petitprez et al.   NATURE

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research

(2020) Corrie A. Painter et al.   NATURE MEDICINE

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab

(2020) Ciara M. Kelly et al.   JAMA Oncology

RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma

(2020) Henry G Smith et al.   EMBO Molecular Medicine

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study

(2020) Jianliang Yang et al.   EUROPEAN JOURNAL OF CANCER

Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report

(2020) Yuki Iijima et al.   Immunotherapy

Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).

(2020) Christina Lynn Roland et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.

(2020) James Lin Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.

(2020) Neeta Somaiah et al.   JOURNAL OF CLINICAL ONCOLOGY

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

(2020) Antoine Italiano et al.   Journal of Hematology & Oncology

Upregulated MELK Leads to Doxorubicin Chemoresistance and M2 Macrophage Polarization via the miR-34a/JAK2/STAT3 Pathway in Uterine Leiomyosarcoma

(2020) Zhiwei Zhang et al.   Frontiers in Oncology

Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis

(2020) Dionisia Quiroga et al.   BMC CANCER

The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations

(2020) Jing Qiu et al.   Future Medicinal Chemistry

A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas

(2020) Varun Monga et al.   Cancers

Activity and Safety of Geptanolimab (GB226) for patients with unresectable, recurrent or metastatic alveolar soft part sarcoma: a phase 2 single-arm study

(2020) Yuankai Shi et al.   CLINICAL CANCER RESEARCH

Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review

(2020) Maggie Zhou et al.   Immunotherapy

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

(2020) Iván Márquez-Rodas et al.   Science Translational Medicine

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma

(2020) Seth M. Pollack et al.   JAMA Oncology

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

(2020) Anne Y Lai et al.   Journal for ImmunoTherapy of Cancer

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

(2020) Rilan Bai et al.   Biomarker Research

FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors

(2019) Leigh Marcus et al.   CLINICAL CANCER RESEARCH

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

(2019) C Henon et al.   ANNALS OF ONCOLOGY

Outcomes of melanoma soft parts/clear cell sarcoma (MSP/CCS) patients (pts) with immune and targeted therapies.

(2019) Amy Little Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside

(2019) Justin Korfhage et al.   MOLECULAR CANCER RESEARCH

Immunotherapeutic effects of intratumoral nanoplexed poly I:C

(2019) M. Angela Aznar et al.   Journal for ImmunoTherapy of Cancer

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

(2019) David W. Vredevoogd et al.   CELL

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

(2019) William D Tap et al.   LANCET

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

(2019) Ian Judson et al.   LANCET ONCOLOGY

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

(2019) Breelyn A Wilky et al.   LANCET ONCOLOGY

Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas

(2019) Amanda R. Dancsok et al.   MODERN PATHOLOGY

Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance

(2019) Matthew F Pech et al.   eLife

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

(2019) Vaia Florou et al.   Journal for ImmunoTherapy of Cancer

1271PHigh clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study

(2019) J-Y Blay et al.   ANNALS OF ONCOLOGY

Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report

(2019) Kohichi Takada et al.   Thoracic Cancer

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

(2019) Indu Ramachandran et al.   Journal for ImmunoTherapy of Cancer

Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors

(2019) Amaury Leruste et al.   CANCER CELL

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

(2019) Birgit Geoerger et al.   LANCET ONCOLOGY

CD163 is required for protumoral activation of macrophages in human and murine sarcoma

(2018) Daisuke Shiraishi et al.   CANCER RESEARCH

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

(2018) Masoud F. Tavazoie et al.   CELL

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

(2018) Sandra P D'Angelo et al.   LANCET ONCOLOGY

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma

(2018) Xiaoyang Li et al.   Cell Death & Disease

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma

(2018) Sandra P. D'Angelo et al.   Cancer Discovery

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

(2018) David A. Schaer et al.   Cell Reports

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway

(2018) Ilaria Grazia Zizzari et al.   Cancer Immunology Research

Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft Part Sarcoma

(2018) Jeremy Lewin et al.   Cancer Immunology Research

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

(2018) Maud Toulmonde et al.   JAMA Oncology

Targeting Macrophages in Cancer: From Bench to Bedside

(2018) Ashleigh R. Poh et al.   Frontiers in Oncology

Pilot study of NY-ESO-1c259 T cells in advanced myxoid/round cell liposarcoma.

(2018) Sandra P. D'Angelo et al.   JOURNAL OF CLINICAL ONCOLOGY

PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.

(2018) Maud Toulmonde et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma

(2018) Luca Paoluzzi et al.   JAMA Oncology

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

(2017) Suzanne George et al.   IMMUNITY

Potential targeting of B7-H4 for the treatment of cancer

(2017) Joseph R. Podojil et al.   IMMUNOLOGICAL REVIEWS

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action

(2017) Wenwen Du et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment

(2017) Marcella Tazzari et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

(2017) Hussein A Tawbi et al.   LANCET ONCOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1

(2017) Kunio Iura et al.   VIRCHOWS ARCHIV

TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis

(2017) Yang Zhang et al.   Oncotarget

PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy

(2017) Melanie Boxberg et al.   OncoImmunology

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

(2017) Roman Groisberg et al.   Journal for ImmunoTherapy of Cancer

Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma

(2016) Chan Kim et al.   BMC CANCER

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib

(2016) Mark A. Dickson et al.   JAMA Oncology

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

(2015) Sandra P. D’Angelo et al.   HUMAN PATHOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

T-cell exhaustion in the tumor microenvironment

(2015) Y Jiang et al.   Cell Death & Disease

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets

(2015) Sujana Movva et al.   Oncotarget

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy

(2014) M Tazzari et al.   BRITISH JOURNAL OF CANCER

Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs

(2014) P. P. Patwardhan et al.   CLINICAL CANCER RESEARCH

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors

(2014) William Lee et al.   NATURE GENETICS

Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies

(2014) Mark Linch et al.   Nature Reviews Clinical Oncology

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells

(2014) Seth M Pollack et al.   Journal for ImmunoTherapy of Cancer

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification

(2013) Christopher D M Fletcher   HISTOPATHOLOGY

Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors

(2013) Franziska Stehle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells

(2013) B. J. Cameron et al.   Science Translational Medicine

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

(2012) Seth M. Pollack et al.   CANCER

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

(2011) M J M Gooden et al.   BRITISH JOURNAL OF CANCER

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

(2010) K. N. Kodumudi et al.   CLINICAL CANCER RESEARCH

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

(2009) W M Liu et al.   BRITISH JOURNAL OF CANCER

Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas

(2008) C.-H. Lee et al.   CLINICAL CANCER RESEARCH